Going Virtual

08/05/2020 By Andrea

Contributing Author: Chris Mycek, President at WORLEY Pivoting to virtual….Google it, you’ll find it’s a common current theme that will have enduring repercussions on how things get done. Zoom is a new household word, and now a verb as well. Amazon Prime, Netflix, FedEx, are all booming. Nesting at home, with new entertainment centers, pools, […]

Speaking the Language of Powders

03/13/2020 By Andrea

Author: Casey Muench Bickhardt, President, GEMCO In the pharmaceutical industry, the precise mixing and drying of powders can be critical to the safety, consistency, performance, and cost effectiveness of a wide range of tablets and capsules with trace levels of additives and active ingredients. A host of variables, such as powder size, shape, density, chemistry, […]

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

08/07/2020

There are no HER3 directed therapies approved for the treatment of NSCLC or any cancer. The frequency of HER3 overexpression in EGFR-mutated NSCLC has been reported to be The post Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated … [Read More...]

ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato

08/07/2020

The approval will enable ViiV Healthcare to use the complete regimen as a replacement for the current antiretroviral (ARV) regimen in adults who are virologically suppressed on a The post ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato appeared first on Pharmaceutical Business … [Read More...]

J&J announces agreement with US govt for 100 million doses of investigational Covid-19 vaccine

08/06/2020

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, in The post J&J announces agreement with US govt for 100 million doses of investigational Covid-19 … [Read More...]

LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer

08/06/2020

The results were reviewed by an independent Data Monitoring Committee (DMC) at a planned interim analysis. The safety profile for lorlatinib and crizotinib were consistent with what has The post LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer … [Read More...]

Featured Article

Going Virtual

Speaking the Language of Powders

White Papers

Whitepaper: Execute a 5-Step Framework for Data Compliance in Healthcare Marketing in the 2020s

Improving HCP Attendance

Industry News

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato

J&J announces agreement with US govt for 100 million doses of investigational Covid-19 vaccine

LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer